Myasthenia gravis and the neuromuscular junction

Current Opinion in Neurology

Volumn 26, Issue 5, 2013, Pages 459-465

  Querol, Luis ^a   Illa, Isabel ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ECULIZUMAB; IMMUNOGLOBULIN; IMMUNOGLOBULIN G4; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MUSK ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ALGORITHM; GENETIC RISK; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INCIDENCE; INNATE IMMUNITY; KNOWLEDGE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; POSTOPERATIVE COMPLICATION; REGULATORY T LYMPHOCYTE; RELAPSE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STEROID THERAPY; THYMECTOMY; THYMUS;

ANIMALS; AUTOANTIBODIES; HUMANS; MYASTHENIA GRAVIS; MYASTHENIC SYNDROMES, CONGENITAL; NEUROMUSCULAR JUNCTION; RECEPTORS, CHOLINERGIC; RISK FACTORS;

EID: 84883750018     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328364c079     Document Type: Review

References (87)

1. Engel AG, Shen XM, Selcen D, Sine S. New horizons for congenital myasthenic syndromes. Ann N Y Acad Sci 2012; 1275:54-62.
2. Abicht A, Dusl M, Gallenmuller C, et al. Congenital myasthenic syndromes: Achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: A study of 680 patients. Hum Mutat 2012; 33:1474-1484.
3. Cossins J, Belaya K, Hicks D, et al. Congenital myasthenic syndromes due to mutations in ALG2 and ALG14. Brain 2013; 136:944-956.
4. Shen XM, Brengman JM, Edvardson S, et al. Highly fatal fast-channel syndrome caused by AChR epsilon subunit mutation at the agonist binding site. Neurology 2012; 79:449-454.
5. Walogorsky M, Mongeon R, Wen H, et al. Zebrafish model for congenital myasthenic syndrome reveals mechanisms causal to developmental recovery. Proc Natl Acad Sci U S A 2012; 109:17711-17716.
6. Maselli RA, Fernandez JM, Arredondo J, et al. LG2 agrin mutation causing severe congenital myasthenic syndrome mimics functional characteristics of nonneural (z-) agrin. Hum Genet 2012; 131:1123-1135.
7. Shen XM, Brengman JM, Sine SM, Engel AG. Myasthenic syndrome AChR alpha C-loop mutant disrupts initiation of channel gating. J Clin Invest 2012; 122:2613-2621.
8. Ohno K, Ito M, Kawakami Y, et al. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis. Chem Biol Interact 2013; 203:335-340.
9. Burke G, Hiscock A, Klein A, et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 2013; 23:170-175.
10. Chan SH, Wong VC, Engel AG. Neuromuscular junction acetylcholinesterase deficiency responsive to albuterol. Pediatr Neurol 2012; 47:137-140.
11. Sabater L, Hoftberger R, Boronat A, et al. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. PLoS One 2013; 8:e60438.
12. Titulaer MJ, Maddison P, Sont JK, et al. Clinical Dutch-English Lambert-Eaton Myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 2011; 29:902-908.
13. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: A case series. Lancet Neurol 2010; 9:776-785.
14. Lancaster E, Huijbers MG, Bar V, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69:303-311.
15. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: Clinical and serological observations in 29 cases. Ann Neurol 2012; 72:241-255.
16. Lavrnic D, Basta I, Rakocevic-Stojanovic V, et al. Epidemiological study of adult-onset myasthenia gravis in the area of Belgrade (Serbia) in the period 1979-2008. Neuroepidemiology 2013; 40:190-194.
17. Montomoli C, Citterio A, Piccolo G, et al. Epidemiology and geographical variation of myasthenia gravis in the province of Pavia, Italy. Neuroepidemiology 2012; 38:100-105.
18. Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol 2010; 10:46.
19. Gattellari M, Goumas C, Worthington JM. A national epidemiological study of myasthenia gravis in Australia. Eur J Neurol 2012; 19:1413-1420.
20. Heldal AT, Eide GE, Gilhus NE, Romi F. Geographical distribution of a seropositive myasthenia gravis population. Muscle Nerve 2012; 45:815-819.
21. Aranow C. Vitamin D and the immune system. J Inves Med 2011; 59:881-886.
22. Askmark H, Haggard L, Nygren I, Punga AR. Vitamin D deficiency in patients with myasthenia gravis and improvement of fatigue after supplementation of vitamin D3: A pilot study. Eur J Neurol 2012; 19:1554-1560.
23. Giraud M, Vandiedonck C, Garchon HJ. Genetic factors in autoimmune myasthenia gravis. Ann N Y Acad Sci 2008; 1132:180-192.
24. Matsuki K, Juji T, Tokunaga K, et al. HLA antigens in Japanese patients with myasthenia gravis. J Clin Invest 1990; 86:392-399.
25. Maniaol AH, Elsais A, Lorentzen AR, et al. Late onset myasthenia gravis is associated with HLA DRB1-15:01 in the Norwegian population. PLoS One 2012; 7:e36603.
26. Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibodypositive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006; 66:1772-1774.
27. Provenzano C, Ricciardi R, Scuderi F, et al. PTPN22 and myasthenia gravis: Replication in an Italian population and meta-analysis of literature data. Neuromuscul Disord 2012; 22:131-138.
28. van der Pol WL, Jansen MD, Kuks JB, et al. Association of the Fc gamma receptor IIA-R/R131 genotype with myasthenia gravis in Dutch patients. J Neuroimmunol 2003; 144:143-147.
29. Raknes G, Skeie GO, Gilhus NE, et al. FcgammaRIIA and FcgammaRIIIB polymorphisms in myasthenia gravis. J Neuroimmunol 1998; 81:173-176.
30. Giraud M, Taubert R, Vandiedonck C, et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007; 448:934-937.
31. Garchon HJ, Djabiri F, Viard JP, et al. Involvement of human muscle acetylcholine receptor alpha-subunit gene (CHRNA) in susceptibility to myasthenia gravis. Proc Natl Acad Sci U S A 1994; 91:4668-4672.
32. Gregersen PK, Kosoy R, Lee AT, et al. Risk for myasthenia gravis maps to a (151) Pro->Ala change in TNIP1 and to human leukocyte antigen-B-08.
33. Nanda SK, Venigalla RK, Ordureau A, et al. Polyubiquitin binding to ABIN1 is required to prevent autoimmunity. J Exp Med 2011; 208:1215-1228.
34. Feng HY, Liu WB, Luo CM, et al. A retrospective review of 15 patients with familial myasthenia gravis over a period of 25 years. Neurol Sci 2012; 33:771-777.
35. Corda D, Deiana GA, Mulargia M, et al. Familial autoimmune MuSK positive myasthenia gravis. J Neurol 2011; 258:1559-1560.
36. Landoure G, Knight MA, Stanescu H, et al. A candidate gene for autoimmune myasthenia gravis. Neurology 2012; 79:342-347.
37. Pal Z, Varga Z, Semsei A, et al. Interleukin-4 receptor alpha polymorphisms in autoimmune myasthenia gravis in a Caucasian population. Hum Immunol 2012; 73:193-195.
38. Zhang J, Chen Y, Jia G, et al. FOXP3-3279 and IVS9+459 polymorphisms are associated with genetic susceptibility to myasthenia gravis. Neurosci Lett 2013; 534:274-278.
39. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: Emerging clinical and biological heterogeneity. Lancet Neurol 2009; 8:475-490.
40. Bartoccioni E, Scuderi F, Minicuci GM, et al. Anti-MuSK antibodies: Correlation with myasthenia gravis severity. Neurology 2006; 67:505-507.
41. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol 2011; 23:119-124.
42. van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013; 131:1204-1212.
43. van der Neut Kolfschoten M, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554-1557.
44. Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012; 135:1081-1101.
45. Richman DP, Nishi K, Morell SW, et al. Acute severe animal model of antimuscle-specific kinase myasthenia: Combined postsynaptic and presynaptic changes. Arch Neurol 2012; 69:453-460.
46. Mori S, Kubo S, Akiyoshi T, et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012; 180:798-810.
47. Morsch M, Reddel SW, Ghazanfari N, et al. Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors. Exp Neurol 2012; 237:286-295.
48. Viegas S, Jacobson L, Waters P, et al. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 2012; 234:506-512.
49. Mori S, Kishi M, Kubo S, et al. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK antibody-induced mouse model of myasthenia gravis. J Neuroimmunol 2012; 245:75-78.
50. Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011; 77:1819-1826.
51. Morsch M, Reddel SW, Ghazanfari N, et al. Pyridostigmine but not 3,4-diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle specific kinase autoantibody. J Physiol 2013; 591:2747-2762.
52. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to lowdensity lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69:418-422.
53. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259:427-435.
54. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69:445-451.
55. Leite MI, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology 2012; 78:1601-1607.
56. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008; 131:1940-1952.
57. Jacob S, Viegas S, Leite MI, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol 2012; 69:994-1001.
58. Masuda T, Motomura M, Utsugisawa K, et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry 2012; 83:935-940.
59. Vrolix K, Fraussen J, Molenaar PC, et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010; 43:380-400.
60. Kinnunen T, Chamberlain N, Morbach H, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood 2013; 121:1595-1603.
61. Xu WH, Zhang AM, Ren MS, et al. Changes of Treg-associated molecules on CD4+CD25+Treg cells in myasthenia gravis and effects of immunosuppressants. J Clin Immunol 2012; 32:975-983.
62. Chuang WY, Strobel P, Gold R, et al. A CTLA4high genotype is associated with myasthenia gravis in thymoma patients. Ann Neurol 2005; 58:644-648.
63. Wang XB, Kakoulidou M, Qiu Q, et al. CDS1 and promoter single nucleotide polymorphisms of the CTLA-4 gene in human myasthenia gravis. Genes Immun 2002; 3:46-49.
64. McIntosh KR, Linsley PS, Bacha PA, Drachman DB. Immunotherapy of experimental autoimmune myasthenia gravis: Selective effects of CTLA4Ig and synergistic combination with an IL2-diphtheria toxin fusion protein. J Neuroimmunol 1998; 87:136-146.
65. Hurst J, von Landenberg P. Toll-like receptors and autoimmunity. Autoimmun Rev 2008; 7:204-208.
66. Bernasconi P, Barberis M, Baggi F, et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005; 167:129-139.
67. Wang YZ, Yan M, Tian FF, et al. Possible involvement of toll-like receptors in the pathogenesis of myasthenia gravis. Inflammation 2013; 36:121-130.
68. Cufi P, Dragin N, Weiss JM, et al. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2012; 73:281-293.
69. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010; 67:726-738.
70. Kakalacheva K, Maurer MA, Tackenberg B, et al. Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann Neurol 2011; 70:508-514.
71. Meyer M, Hols AK, Liersch B, et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann Neurol 2011; 70:515-518.
72. Csuka D, Banati M, Rozsa C, et al. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012; 19:842-846.
73. Thamilarasan M, Koczan D, Hecker M, et al. MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. Autoimmun Rev 2012; 11:174-179.
74. Cheng Z, Qiu S, Jiang L, et al. MiR-320a is downregulated in patients with myasthenia gravis and modulates inflammatory cytokines production by targeting mitogen-activated protein kinase 1. J Clin Immunol 2013; 33: 567-576.
75. Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011; 76:2017-2023.
76. Barnett C, Wilson G, Barth D, et al. Changes in quality of life scores with intravenous immunoglobulin or plasmapheresis in patients with myasthenia gravis. J Neurol Neurosurg Psychiatry 2013; 84:94-97.
77. Cheng C, Liu Z, Xu F, et al. Clinical outcome of juvenile myasthenia gravis after extended transsternal thymectomy in a chinese cohort. Ann Thorac Surg 2013; 95:1035-1041.
78. Jurado J, Javidfar J, Newmark A, et al. Minimally invasive thymectomy and open thymectomy: Outcome analysis of 263 patients. Ann Thorac Surg 2012; 94:974-981; discussion 981-982.
79. Marulli G, Schiavon M, Perissinotto E, et al. Surgical and neurologic outcomes after robotic thymectomy in 100 consecutive patients with myasthenia gravis. J Thorac Cardiovasc Surg 2013; 145:730-735; discussion 735-736.
80. Cutter G. Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy. http://clinicaltrials gov/ct2/show/NCT00294658 2012; 2013.
81. Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and nonrefractory myasthenia: A retrospective multicenter study. Muscle Nerve 2012; 46:687-691.
82. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78:189-193.
83. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357:545-552.
84. Maurer MA, Rakocevic G, Leung CS, et al. Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity. J Clin Invest 2012; 122:1393-1402.
85. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2:797-804.
86. Howard JF Jr, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve 2013; 48:76-84.
87. Huda R, Tuzun E, Christadoss P. Complement C2 siRNA mediated therapy of myasthenia gravis in mice. J Autoimmun 2013; 42:94-104.